EDITORIAL SECTION

  • STRATEGY

    Smarter Pharma

    Quality management systems QMS are the backbone of pharmaceutical manufacturing ensuring safe products

  • EXPERT Talk

    Compliance to Competitive Advantage in Pharma Supply

    Compliance gets you through an audit Resilience gets medicines to patients on the day something unexpected happens The DSCSAs enhanced requirements took effect November but real interoperability required three more rounds of accommodation phased implementation with the smalldispenser

KNOWLEDGE BANK

TOP ARTICLES

press releases Read more...

Biocodex Invests €15 Million in a New Industrial Platform for Live Biotherapeutic Products

Biocodex an independent French pharmaceutical company announces a million investment to develop an industrial platform in Beauvais France dedicated to Live Biotherapeutic Products LBPs derived from the microbiome Building on more than years of expertise in living microorganisms microbiota fermenta...

Boehringer Ingelheim and SBP Group enter partnership to advance next-generation cancer therapies

Boehringer Ingelheim headquartered in Germany and Sino Biopharmaceutical Limited HK together with its subsidiaries SBP Group today announced a strategic multiprogram option and license agreement to advance potential nextgeneration cancer treatments based on antibodydrug conjugate ADC and Tcell engag...

Nxera Pharma Enters into Global License Agreement with AbbVie for NXE0033744, a Novel EP4 Receptor Agonist for Inflammatory Bowel Disease

Nxera Pharma Co Ltd announces that its subsidiary Nxera Pharma UK Ltd has entered into an exclusive global license agreement the Agreement with AbbVie Inc AbbVie for Nxeras EP agonist program including NXE a novel small molecule EP receptor agonist discovered

Oryzon announces authorization in Spain of VIVALDI, a collaborative clinical study with CETLAM to evaluate iadademstat in combination with standard-of-care therapy in high-risk newly-diagnosed AML subpopulations

Oryzon Genomics SA a clinicalstage biopharmaceutical company and global leader in epigenetics today announced that VIVALDI a Phase Ib pilot study sponsored by CETLAM Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplsicas has been authorized in Spain

09 - 11

Nov 2026

11th Microbiome Movement USA Summit

The Colonnade Hotel, Boston, M...

10 - 11

Nov 2026

Extractables & Leachables Europe

Parkhotel Schӧnbrunn, Vienna,...

10 - 10

Nov 2026

Women in AI

Real Chemistry, 2nd Floor, Lon...

11 - 13

Nov 2026

Frontiers in Cancer Science 2026

One Farrer Hotel,1 Farrer Park...

11 - 12

Nov 2026

24 - 25

Nov 2026

24 - 27

Nov 2026

Pharmtech & Ingredients 2026

Crocus Expo, Pavilion 2, Mosco...

LATEST NEWS Read more...

Portal Innovations and Altitude Lab Partner to Strengthen Utah’s Life Sciences Startup Ecosystem

Portal Innovations a venture development platform supporting earlystage life sciences companies today announced a strategic partnership with Altitude Lab to strengthen the resources available to life sciences entrepreneurs in Salt Lake City Through the partnership Altitude Lab will relocate its acce...

MRM Health and Biocodex establish strategic partnership to strengthen future commercial supply capabilities for CORAL®-based medicines

MRM Health a clinicalstage biotech developing microbiomebased therapies for immunemediated diseases and Biocodex an independent French pharmaceutical company with more than years of experience in the microbiome field today announced the launch of a strategic partnership to establish specialized man...

Breakthrough Therapy Designation granted by the FDA for daridorexant in pediatric insomnia disorder

Idorsia Ltd announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy Designation to daridorexant for the treatment of insomnia disorder in patients to

Evestia Clinical Acquires Emtex Life Science to Further Enhance its Global Full-Service Clinical Research Capabilities

Evestia Clinical a leading independent global specialist Contract Research Organization CRO today announced the acquisition of Emtex Life Science Emtex a specialist regulatory medical writing company headquartered in Belgium The acquisition strengthens Evestia

UroGen Announces First Patient Dosed in Phase 1 Trial of UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer

UroGen Pharma Ltd a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers today announced that the first patient was dosed with UGN a nextgeneration investigational oncolytic virus The Phase trial will evaluate the safety tolera...

Graviton BioScience and CinRx Pharma Form CinRock Pharma to Advance ROCK2-Targeted Therapies for Cardiovascular Disease

Graviton BioScience Corporation Graviton and CinRx Pharma CinRx today announced the formation of CinRock Pharma CinRock a jointly governed biopharmaceutical company established to accelerate the development of novel ROCKtargeted therapies for patients with cardiovascular diseases